On April 29, 2020, the United States Trade Representative (USTR) published its annual Special 301 Report. A PDF copy of the report is available here. KEI has compiled copies of the Special 301 Report for every year since its inception… Continue Reading →
Background In 2001, the World Trade Organization (WTO) began negotiations on the rules regarding patents and access to medicine. While several issues were clarified and resolved in the November 2001 “Doha Declaration on TRIPS and Public Health”, the negotiations took… Continue Reading →
Today, the Office of the United States Trade Representative hosted the hearing for the annual Special 301 Review. The review process includes a solicitation of written comments and hearing testimony, and results in the publication of the Special 301 Report.… Continue Reading →
On Friday, 14 February 2020, Knowledge Ecology International (KEI) submitted the following comments on the Draft General Comment on Science and economic, social and cultural rights prepared by the the Committee on Economic, Social and Cultural rights (CESCR). The draft… Continue Reading →
EU-Mercosur-IP-Chapter We will add more extensive notes next week. But a few items are worth noting,including, to start, the Principals. Article X.4 Principles 1. Each Party recognises that the protection and enforcement of intellectual property rights can and must be… Continue Reading →
Through a Freedom of Information Act request, KEI has obtained records relating to US Trade Representative Ambassador Robert Lighthizer’s attendance at the 2018 World Economic Forum in Davos, Switzerland. While many of the records were related to scheduling and re-scheduling… Continue Reading →
A comment on the damages provision in the USMCA IP Chapter was published on April 2, 2019, in Harvard’s Bill of Health blog, here.
This timeline provides copies of official documents not published before about the U.S. pressures in the Dominican Republic during the congressional debates that led to the adoption of the TRIPS-implementing legislation Law 20-00. These documents were obtained via FOIA requests.… Continue Reading →
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading →
On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading →